Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14365542 | 0.80 | — | — | |
| SCHEMBL12733712 | 0.76 | RGS4 (0.32) | RGS4RGS8 | |
| SCHEMBL22108755 | 0.73 | RGS4 (0.30) | RGS4RGS8 | |
| SCHEMBL13216890 | 0.70 | ADORA2B (0.31) | — | |
| SCHEMBL13216897 | 0.68 | — | — | |
| SCHEMBL19195115 | 0.65 | RGS4 (0.31) | RGS4RGS8 | |
| SCHEMBL12109538 | 0.65 | RGS4 (0.36) | RGS4RGS8 | |
| SCHEMBL14926019 | 0.62 | LMNA (0.31) | — | |
| SCHEMBL22036406 | 0.62 | RGS4 (0.41) | RGS4RGS8 | |
| SCHEMBL24375216 | 0.60 | ADORA3 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | BACE1, ENGASE, GBA3 | RGS4 4385/4885RGS8 2683/4885 |
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | PTPN1, PTPN7, PTPN9 | RGS4 1343/4885RGS8 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.